ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.


ORTHOCON® Announces Signing of Exclusive, Worldwide License Agreement with Bezwada Biomedical
August 31, 2011 - Click to Download

ORTHOCON® Receives 510(k) Clearance to Market HEMASORB Apply™
June 1, 2011 - Click to Download